GLP-1 and Cardiovascular Effects: Systematic Review with ☸️SAIMSARA.
SAIMSARA Journal · 2026
DOI: 10.62487/saimsarafcc6e977 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift SAIMSARA Journal, 2026.
Abstract (Originalsprache)
The aim of this systematic review is to comprehensively synthesize the current scientific literature on the cardiovascular effects of GLP-1 receptor agonists, including their efficacy in reducing adverse cardiovascular outcomes, their mechanisms of action, and their impact across various patient populations and comorbidities. The review utilises 2029 studies with 19288729 total participants (naïve ΣN). GLP-1 receptor agonists have fundamentally reshaped the landscape of cardiovascular disease management, particularly in patients with T2DM and obesity. This systematic review highlights their consistent efficacy in reducing major adverse cardiovascular events (MACE) and improving a spectrum of cardiovascular risk factors. The median reduction in MACE was 0.795, underscoring their significant cardioprotective role across diverse populations and comorbidities. While the heterogeneity of study designs and reporting presents a limitation, the collective evidence firmly establishes GLP-1 RAs as essential therapies. Future research should prioritize comparative effectiveness trials among different GLP-1 RA agents and focus on optimizing their real-world implementation to ensure equitable access and maximize population health benefits.
Zitieren
APA
(2026). GLP-1 and Cardiovascular Effects: Systematic Review with ☸️SAIMSARA. SAIMSARA Journal. https://doi.org/10.62487/saimsarafcc6e977
Vancouver
GLP-1 and Cardiovascular Effects: Systematic Review with ☸️SAIMSARA. SAIMSARA Journal. 2026. doi:10.62487/saimsarafcc6e977
BibTeX
@article{euvimed2026,
title = {GLP-1 and Cardiovascular Effects: Systematic Review with ☸️SAIMSARA},
journal = {SAIMSARA Journal},
year = {2026},
doi = {10.62487/saimsarafcc6e977}
}
EUVIMED